Next-Gen Antibody Therapeutics Market to Hit $4.1B by 2030, Growing at 7.6% CAGR

NEW YORK - Feb. 24, 2025 - PRLog -- e global next-generation antibody therapeutics market is poised for significant growth, with projections indicating an increase from USD 2,686.2 million in 2024 to USD 4,139.1 million by 2030, reflecting a compound annual growth rate (CAGR) of 7.6% during the forecast period.

This expansion is primarily driven by advancements in monoclonal antibody technology, which offer enhanced safety and efficacy profiles. Additionally, the rising prevalence of chronic diseases, such as cancer and autoimmune disorders, necessitates innovative therapeutic solutions, further propelling market growth. The oncology sector, in particular, dominates the therapeutic area, accounting for approximately 90% of the market share in 2024.

Key Insights

Therapeutic Area Analysis

The oncology segment holds a dominant position, representing about 90% of the market share in 2024. This is attributed to the escalating incidence of cancers, including breast, colorectal, prostate, brain, and lung cancers. Next-generation antibody therapeutics offer targeted treatment options, minimizing damage to healthy tissues and reducing side effects. Notable therapeutics such as Kadcyla, ADCETRIS, and Poteligeo have been instrumental in treating various cancers, thereby boosting market revenue.

Browse detailed report analysis on "Next-Gen Antibody Therapeutics Market Growth Report, 2030 (https://www.psmarketresearch.com/market-analysis/next-gen...)"

Regional and Geographical Trends

North America stands as the largest market, valued at around USD 1.1 billion in 2024. Factors such as substantial R&D funding, a high prevalence of chronic diseases, and the presence of key industry players contribute to this dominance. The U.S. and Canada are pivotal markets within the region. Conversely, the Asia-Pacific region is projected to witness the highest CAGR of approximately 9% during the forecast period. This growth is driven by strategic partnerships, increased R&D activities in countries like China, India, and Japan, and supportive government initiatives fostering pharmaceutical manufacturing.

Technological Advancements

The adoption of ADC technology is a prominent trend, attributed to its potential benefits in chemotherapy due to the cytotoxic nature of antibodies. Pharmaceutical and biotechnology companies are increasingly focusing on developing ADCs, recognizing their high efficiency and specificity in targeting cancer cells. Technological innovations in glycoengineered antibodies and bispecific antibodies further enhance the therapeutic potential, offering improved characteristics and expanding treatment possibilities.

Competitive Dynamics and Emerging Opportunities

The market is consolidated, with major players such as F. Hoffmann-La Roche, AstraZeneca plc, and ImmunoGen Inc. leading the landscape. These companies are at the forefront of developing cutting-edge ADCs and monoclonal antibodies targeting oncological and autoimmune diseases. Continuous technological innovations and robust research activities are paving the way for new therapeutic targets, presenting lucrative opportunities for market expansion and the introduction of advanced treatment modalities.